Rapamycin for treatment of type i autosomal dominant polycystic kidney disease (RAPYD-study): A randomized, controlled study

Giovanni Stallone, Barbara Infante, Giuseppe Grandaliano, Christos Bristogiannis, Luca MacArini, Daniela Mezzopane, Francesca Bruno, Eustacchio Montemurno, Annalisa Schirinzi, Massimo Sabbatini, Antonio Pisani, Tiziana Tataranni, Francesco Paolo Schena, Loreto Gesualdo

Research output: Contribution to journalArticle

Abstract

Background. Autosomal dominant polycystic kidney disease (ADPKD) is the most common form of cystic kidney disease. An inappropriate stimulation of mammalian target of rapamycin may represent the converging point in the molecular pathways leading to renal cyst growth. Methods. The primary objectives of this prospective, open-label, randomized clinical trial were to assess whether rapamycin may reduce the progressive increase in single cyst and total kidney volume in type I ADPKD and the decline in renal function and to identify the optimal rapamycin dose. Fifty-five patients with type I ADPKD were enrolled and randomized to receive ramipril (Group A), ramipril high-dose rapamycin (Group B, trough level 68 ng/mL) and ramipril low-dose rapamycin (Group C, trough levels 24 ng/mL). Rapamycin efficacy was monitored measuring p70 phosphorylation in peripheral blood mononuclear cells. Results. Both rapamycin doses significantly reduced p70 phosphorylation. Nevertheless, total kidney volume increased in all groups after 24 months, although only in Groups A and B, was the final volume significantly higher compared with the baseline. Single cyst final volume was not significantly different in the three groups, although it was increased in Group A compared with the baseline, whereas in Groups B and C, it was significantly reduced. We did not observe any difference in renal function at 24 months among the three study groups. Group A presented a significant worsening of renal function that remained stable in both Groups B and C. Conclusions. Our study would suggest that rapamycin does not influence the progression of type I ADPKD, although the higher drug dose tested prevented both the increase in kidney volume and the worsening of renal function (RAPYD-study, EUDRACT No. 2007-006557-25).

Original languageEnglish
Pages (from-to)3560-3567
Number of pages8
JournalNephrology Dialysis Transplantation
Volume27
Issue number9
DOIs
Publication statusPublished - Sep 2012

Keywords

  • ADPKD
  • cyst volume
  • kidney function
  • kidney volume
  • rapamycin

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Fingerprint Dive into the research topics of 'Rapamycin for treatment of type i autosomal dominant polycystic kidney disease (RAPYD-study): A randomized, controlled study'. Together they form a unique fingerprint.

  • Cite this

    Stallone, G., Infante, B., Grandaliano, G., Bristogiannis, C., MacArini, L., Mezzopane, D., Bruno, F., Montemurno, E., Schirinzi, A., Sabbatini, M., Pisani, A., Tataranni, T., Schena, F. P., & Gesualdo, L. (2012). Rapamycin for treatment of type i autosomal dominant polycystic kidney disease (RAPYD-study): A randomized, controlled study. Nephrology Dialysis Transplantation, 27(9), 3560-3567. https://doi.org/10.1093/ndt/gfs264